News & Updates
Filter by Specialty:
Hands-free, pocket-size device helps ease breathing for people with COPD
A small positive-expiratory pressure (PEP) device that can be used on-demand shows promise for improving the lives of people with chronic obstructive pulmonary disease (COPD), according to a study.
Hands-free, pocket-size device helps ease breathing for people with COPD
27 Mar 2023
Chemotherapy plus ICI treatment ups VTE risk in cancer patients
Combination treatment with immune checkpoint inhibitors (ICI) and chemotherapy is associated with a higher risk of venous thromboembolic events (VTE) in adult cancer patients, reveals a study. In addition, a similar VTE disease course is seen after ICI exposure, irrespective of other immune-related adverse events (irAEs).
Chemotherapy plus ICI treatment ups VTE risk in cancer patients
27 Mar 2023
Oral, on-the-skin immunotherapies show promise against peanut allergy in children
Children who are allergic to peanuts may benefit from two immunotherapies, one oral and another epicutaneous or on-the-skin, which have demonstrated safety and efficacy in separate studies presented at the recent AAAAI 2023.
Oral, on-the-skin immunotherapies show promise against peanut allergy in children
27 Mar 2023
CAB+RPV LA vs B/FTC/TAF for HIV: Which is better?
In virologically suppressed adults with HIV, the cabotegravir + rilpivirine long-acting (CAB+RPV LA) regimen was on par with bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF) in terms of virologic efficacy, but the former gained the upper hand over the latter in terms of patient satisfaction and preference, the SOLAR* study reports.
CAB+RPV LA vs B/FTC/TAF for HIV: Which is better?
27 Mar 2023
Polysaccharide hemostatic powder shows promise for peptic ulcer bleeding
In the initial endoscopic treatment of peptic ulcer bleeding, the use of polysaccharide hemostatic powder appears to be not less efficacious than conventional treatment, according to a study.
Polysaccharide hemostatic powder shows promise for peptic ulcer bleeding
27 Mar 2023
Ondansetron shows potential in irritable bowel syndrome with diarrhoea
A study on titrated ondansetron for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) has fallen short of meeting the endpoint due to being underpowered. However, when data from this study and two others were pooled in a meta-analysis, ondansetron appears to yield significant improvements in the composite endpoint set by the Food and Drug Administration (FDA), namely stool consistency and urgency.
